Prostate Cancer - Results from #23720

Bone-targeting radiopharmaceuticals including radium-223 - Abstract February 27, 2013

Standardized comparison of robot-assisted limited and extended pelvic lymphadenectomy for prostate cancer - Abstract February 27, 2013

Association between use of β-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease - Abstract February 27, 2013

Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone - Abstract February 27, 2013

Prostate cancer and osteoporosis - Abstract February 27, 2013

Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: Comparison with 18F-fluoride uptake - Abstract February 27, 2013

Incidence of prostate, breast, lung and colorectal cancer following new consultation for musculoskeletal pain: A cohort study among UK primary care patients - Abstract February 27, 2013

Fatherhood status and risk of prostate cancer. Nationwide, population-based case-control study - Abstract February 27, 2013

Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance - Abstract February 27, 2013

Androgen deprivation therapy: Evidence-based management of side effects - Abstract February 27, 2013

Osteoporosis knowledge, health beliefs, and healthy bone behaviours in patients on androgen-deprivation therapy (ADT) for prostate cancer - Abstract February 27, 2013

Radiosensitization in prostate cancer: Mechanisms and targets - Abstract February 27, 2013

GU Cancers Symposium 2013 - Poster: Bone health among prostate cancer survivors: Long term follow-up from the prostate cancer outcomes study (PCOS), by Alicia Morgans, MD, et al February 26, 2013

GU Cancers Symposium 2013 - Session Highlights: Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD February 26, 2013

GU Cancers Symposium 2013 - Overall survival and safety of dasatinib/docetaxel vs docetaxel in patients with metastatic castration-resistant prostate cancer: Results from the randomized phase 3 READY trial, by John C. Araujo, MD, PhD, et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Lower risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists, by Peter Albertsen, MD, et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Degarelix versus LHRH agonists: Differential skeletal and urinary tract outcomes from an analysis of six comparative randomized clinical trials, by E. David Crawford, MD et al. - Poster February 26, 2013

GU Cancers Symposium 2013 - Galeterone, abiraterone, orteronel and ketoconazole exhibit differential inhibitory effects on CYP17 and steroidogenesis, by Douglas B. Jacoby and Martin Williams - Poster February 26, 2013

GU Cancers Symposium 2013 - A randomized, phase II, open-label study of sipuleucel-t with concurrent or sequential abiraterone acetate in metastatic castrate-resistant prostate cancer, by Eric J. Small, MD, et al. - Poster February 26, 2013

Prostate cancer brachytherapy: Guidelines overview - Abstract February 26, 2013

Page 1187 of 1435